This policy statement is approved by Halton, Knowsley, Liverpool, Southport and Formby, South Sefton, St Helens, Warrington and West Lancashire CCGs Halton Knowsley Liverpool Southport and Formby South Sefton St Helens Warrington West Lancashire PAN MERSEY AREA PRESCRIBING COMMITTEE PRESCRIBING POLICY STATEMENT Pan Mersey REF: PS204 FINAL Area Prescribing Committee APC BOARD DATE: 28 JUN 2017 CERTOLIZUMAB PEGOL (Cimzia®) and SECUKINUMAB (Cosentyx®▼) in Psoriatic Arthritis The Pan Mersey Area Prescribing Committee recommends the R ® E prescribing of CERTOLIZUMAB PEGOL (Cimzia ) and ® D SECUKINUMAB (Cosentyx ▼), by specialists only, for psoriatic arthritis in accordance with NICE TA445. NICE technology appraisal (TA) 445 recommends certolizumab pegol (Cimzia®), alone or in combination with methotrexate, as an option for treating psoriatic arthritis only if: it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks and the company provides it as agreed in the patient access scheme. NICE technology appraisal (TA) 445 recommends secukinumab (Cosentyx®▼), alone or in combination with methotrexate, as an option for treating psoriatic arthritis only if: it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis) and the company provides it as agreed in the patient access scheme. NICE specifies response and continuation criteria – see TA445 For further information refer to Mersey Biologics Pathway for Psoriatic Arthritis and patients with Peripheral Spondyloarthropathy (SpA) Costing information – NICE state there is no significant change in resource impact anticipated. References 1. NICE TA445, Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs, May 2017. Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes. Version: 1.1 Review date: June 2019 (or earlier if there is significant new evidence relating to this recommendation) .